Impact of high-dose chemotherapy followed by auto-SCT for positive interim 18 F FDG-PET diffuse large B-cell lymphoma patients

Bone Marrow Transplantation

Volumn 46, Issue 3, 2011, Pages 393-399

  Roland, V ^a   Bodet Milin, C ^b   Moreau, A ^b   Gastinne, T ^a   Mahe B ^a   Dubruille, V ^a   Maisonneuve, H ^c   Juge Morineau, N ^d   Moreau, P ^a,e   Jardel, H ^f   Planche, L ^b   Mohty, M ^a,b   Harousseau, J L ^h   Kraeber Bodere F ^b,g,h   Le Gouill, S ^a,b,g  

^a HÔTEL DIEU   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Centre hospitalier Les Oudairies   (France)

^d Service d'Hématologie Clinique   (France)

^e Centre Hospitalier de Lorient   (France)

^f Centre Hospitalier de Vannes   (France)

^g UNIVERSITÉ DE NANTES   (France)

^h CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Auto SCT; FDG PET; lymphoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; IMAGE ANALYSIS; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79952533396     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.130     Document Type: Article

References (24)

1. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586. (Pubitemid 350002966)
2. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578. (Pubitemid 350002965)
3. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomo-graphy (FDG-PET) in aggressive lymphoma: an early prog-nostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381. (Pubitemid 41129604)
4. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295. (Pubitemid 38375363)
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
6. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242. (Pubitemid 34438862)
7. Elias L, Portlock CS, Rosenberg SA. Combination chemother-apy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1978; 42: 1705-1710. (Pubitemid 9053509)
8. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
9. Fru CC, Reman O, Le Stang N, Musafiri D, Cheze S, Macro M et al. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. Leuk Lymphoma 2006; 47: 2547-2557. (Pubitemid 44932645)
10. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107: 2678-2687. (Pubitemid 44845624)
11. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523. (Pubitemid 41222425)
12. Ng AP, Wirth A, Seymour JF, Lee M, Hogg A, Januszewicz H et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy inpatients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma 2007; 48: 596-600. (Pubitemid 46487769)
13. Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodg-kin's disease. Ann Hematol 2006; 85: 759-767. (Pubitemid 44377874)
14. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T et al. Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356-1363.
15. Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of ma-lignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16: 260-267. (Pubitemid 34145144)
16. Crocchiolo R, Canevari C, Assanelli A, Lunghi F, Tassara M, Stanghellini ML et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 2008; 49: 727-733. (Pubitemid 351517218)
17. Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P et al. The impact of pre-and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110: 1361-1369. (Pubitemid 47435610)
18. Schot BW, Pruim J, van Imhoff GW, Sluiter WJ, Vaalburg W, Vellenga E. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 2006; 91: 490-495.
19. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al. Prognostic value of preTransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplant-ation. Blood 2003; 102: 53-59. (Pubitemid 36759635)
20. Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 211-216. (Pubitemid 44102948)
21. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27: 1906-1914.
22. Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007; 48: 1626-1632. (Pubitemid 47572710)
23. Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009; 50: 527-533.
24. Meignan M, Gallamini A, Meignan A, Haioun C Report of the first international workshop on interim Pet-scan in lymphoma. Leuk lymphoma 2009; 50: 1257-1260.